Qualigen Therapeutics Inc represents values of innovation, dedication, and commitment to improving patient outcomes. The company's corporate philosophy revolves around developing novel therapeutic solutions that address unmet medical needs. They aim to leverage their expertise in biotechnology to create effective treatments for various diseases, including cancer and infectious diseases. Qualigen Therapeutics Inc prioritizes excellence in scientific research, clinical development, and commercialization to provide high-quality and accessible healthcare solutions. The company values integrity, collaboration, and patient-centered care, striving to make a positive impact on the lives of patients worldwide with its advanced therapies.

Qualigen Therapeutics Inc is primarily present in the United States.

Qualigen Therapeutics Inc has achieved several significant milestones. One of the notable accomplishments is the development of their FDA-approved FastPack® System, which enables rapid testing for a range of diseases. The company has also made progress in developing their proprietary oligonucleotide nanoparticle drug delivery technology. Additionally, Qualigen Therapeutics has actively conducted clinical trials for various therapeutic candidates, including their lead drug candidate, AS1411. They have also forged partnerships and collaborations with research institutions and pharmaceutical companies for the advancement of their products. Overall, Qualigen Therapeutics Inc has demonstrated its commitment to innovation and contributing to the field of healthcare.

Qualigen Therapeutics Inc is a biotechnology company that specializes in the development and commercialization of innovative cancer therapeutics, diagnostics, and medical devices. Founded in 1996, Qualigen has a rich history of researching and developing novel technologies to address significant unmet needs in the medical industry. The company has made notable advancements in the fields of infectious diseases, women's health, and oncology. With a strong focus on precision medicine and personalized treatments, Qualigen Therapeutics Inc has positioned itself as a key player in the healthcare industry. Continuously striving to improve patient outcomes, the company remains dedicated to advancing the science of diagnosis and treatment.

The main competitors of Qualigen Therapeutics Inc in the market include other biopharmaceutical companies operating in the same therapeutic areas. Key competitors may vary based on the specific products and services offered by Qualigen Therapeutics Inc. Some prominent competitors in the biopharmaceutical industry include Pfizer Inc, Johnson & Johnson, Moderna Inc, and Novartis AG.

Qualigen Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Qualigen Therapeutics Inc. centers around the development and commercialization of innovative therapeutic products. Specifically, the company focuses on the discovery and advancement of novel treatments for cancer and infectious diseases. By leveraging its proprietary technologies and expertise, Qualigen Therapeutics aims to address unmet medical needs and improve patient outcomes. This includes the development of next-generation therapeutics, diagnostics, and drug delivery systems. The company's commitment to research, development, and collaboration with strategic partners positions Qualigen Therapeutics as a leading player in the field of biotechnology, with a strong emphasis on advancing patient care and revolutionizing healthcare solutions.

De Qualigen Therapeutics K/W is -0,07.

De Qualigen Therapeutics KUV is 0.

De AlleAktien Kwaliteitsscore voor Qualigen Therapeutics is 5/10.

De omzet kan momenteel niet worden berekend voor Qualigen Therapeutics.

De verwachte Qualigen Therapeutics winst is -12,40 mln. USD.

Qualigen Therapeutics Inc is an emerging biotechnology company based in the USA. The company focuses on the development and commercialization of innovative therapeutics and diagnostics. Its business activities cover a wide range of products and services in various medical fields. Qualigen Therapeutics' business model is tailored to its various areas of activity. Firstly, the company is engaged in the development of medical products. Qualigen Therapeutics has a number of patented technologies, including the FastPack® Point-of-Care diagnostic systems, which provide it with a competitive advantage. The company has expertise and experience in medical research and development, enabling it to develop new drugs and diagnostic tools in a short period of time. Another important area is the distribution of medications and medical devices. The company offers a wide range of drugs and diagnostics that can be used, for example, in the treatment of cancer, infections, or autoimmune diseases. Qualigen Therapeutics' business is focused on various market segments, such as clinical diagnostics, as well as the pharmaceutical and biotech industries. Furthermore, through partnerships both domestically and internationally, the company is able to expand its reach to bio-pharmaceutical companies in the USA and global markets. Currently, the company is also heavily focused on the development of COVID-19 tests and therapies. Qualigen has described a low-cost COVID-19 rapid test that can be conducted in just a few minutes. They are also developing a therapy named RAS-F, which targets COVID-19 symptoms promisingly. Overall, as an emerging biotechnology company, Qualigen Therapeutics offers a wide range of medical devices, diagnostic, and therapeutic products in various medical fields. Its business model is designed to gain a competitive advantage in different areas of activity and establish a broad market presence. With its unique and patented technology, strong research expertise, and focus on COVID-19 tests and therapies, Qualigen Therapeutics has the potential to become a significant player in the biotech and pharmaceutical industries.

Qualigen Therapeutics keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Qualigen Therapeutics of het bedrijf keert geen dividend uit.

De ISIN van Qualigen Therapeutics is US74754R1032.

Het WKN van Qualigen Therapeutics is A2P5C5.

De ticker van Qualigen Therapeutics is QLGN.

Binnen de laatste 12 maanden betaalde Qualigen Therapeutics een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Qualigen Therapeutics naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Qualigen Therapeutics is momenteel .

Qualigen Therapeutics betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Qualigen Therapeutics betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Qualigen Therapeutics wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Qualigen Therapeutics van 9-9-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 9-9-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 9-9-2024.

In het jaar 2023 heeft Qualigen Therapeutics 0 USD aan dividenden uitgekeerd.

De dividenden van Qualigen Therapeutics worden in USD uitgekeerd.